(VIANEWS) - American Public Education (APEI), Neurocrine Biosciences (NBIX), Globus Medical (GMED) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. American Public Education (APEI)
76.3% sales growth and 7.15% return on equity
American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education.
American Public Education's sales growth this year is expected to be 25.2% and 56.7% for next year.
Year-on-year quarterly revenue growth grew by 18.7%, now sitting on 335.71M for the twelve trailing months.
Volume
Today's last reported volume for American Public Education is 292935 which is 261.87% above its average volume of 80949.
American Public Education's sales growth is a negative 0% for the current quarter and 76.3% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 94.4% and negative -17%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.15%.
Volatility
American Public Education's last day, last week, and last month's current intraday variation average was 2.52%, 2.57%, and 2.95%, respectively.
American Public Education's highest amplitude of average volatility was 3.95% (day), 3.44% (last week), and 4.21% (last month), respectively.
American Public Education's Stock Yearly Top and Bottom Value
American Public Education's stock is valued at $18.89 at 05:22 EST, way under its 52-week high of $39.19 and above its 52-week low of $18.11.
American Public Education's Moving Average
American Public Education's worth is way under its 50-day moving average of $24.12 and way below its 200-day moving average of $28.12.2. Neurocrine Biosciences (NBIX)
30.2% sales growth and 42.19% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.
Neurocrine Biosciences's sales growth this year is expected to be 9% and 23.4% for next year.
Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 1.05B for the twelve trailing months.
Volume
Today's last reported volume for Neurocrine Biosciences is 775507 which is 8.85% above its average volume of 712428.
Neurocrine Biosciences's sales growth for the next quarter is 30.2%. The company's growth estimates for the current quarter and the next is 193.5% and negative -80.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 42.19%.
Volatility
Neurocrine Biosciences's last day, last week, and last month's current intraday variation average was 1.20%, 1.77%, and 1.25%, respectively.
Neurocrine Biosciences's highest amplitude of average volatility was 3.02% (day), 4.63% (last week), and 3.36% (last month), respectively.
Neurocrine Biosciences's Stock Yearly Top and Bottom Value
Neurocrine Biosciences's stock is valued at $79.68 at 05:22 EST, way below its 52-week high of $120.27 and above its 52-week low of $79.01.
Neurocrine Biosciences's Moving Average
Neurocrine Biosciences's value is way below its 50-day moving average of $95.40 and way under its 200-day moving average of $95.52.3. Globus Medical (GMED)
9.5% sales growth and 11.93% return on equity
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders.
Globus Medical's sales growth this year is expected to be 20.6% and 10% for next year.
Year-on-year quarterly revenue growth grew by 6.3%, now sitting on 941.53M for the twelve trailing months.
Volume
Today's last reported volume for Globus Medical is 398762 which is 12.78% below its average volume of 457219.
Globus Medical's sales growth for the next quarter is 9.5%. The company's growth estimates for the current quarter and the next is a negative 19% and 8.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.93%.
Volatility
Globus Medical's last day, last week, and last month's current intraday variation average was 0.77%, 1.31%, and 1.30%, respectively.
Globus Medical's highest amplitude of average volatility was 3.27% (day), 2.51% (last week), and 2.97% (last month), respectively.
Globus Medical's Stock Yearly Top and Bottom Value
Globus Medical's stock is valued at $63.79 at 05:22 EST, way under its 52-week high of $84.23 and above its 52-week low of $58.87.
Globus Medical's Moving Average
Globus Medical's value is way below its 50-day moving average of $75.99 and way under its 200-day moving average of $73.40.4. Target Corporation (TGT)
8% sales growth and 45.98% return on equity
Target Corporation operates as a general merchandise retailer in the United States.
Target Corporation's sales growth this year is expected to be 11.7% and 1.7% for next year.
Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 100.33B for the twelve trailing months.
Volume
Today's last reported volume for Target Corporation is 7739890 which is 146.67% above its average volume of 3137700.
Target Corporation's sales growth is a negative 0% for the current quarter and 8% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 0.4% and 6.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 45.98%.
Volatility
Target Corporation's last day, last week, and last month's current intraday variation average was 0.26%, 0.95%, and 1.69%, respectively.
Target Corporation's highest amplitude of average volatility was 1.29% (day), 1.94% (last week), and 2.56% (last month), respectively.
Target Corporation's Stock Yearly Top and Bottom Value
Target Corporation's stock is valued at $243.84 at 05:22 EST, under its 52-week high of $268.98 and way higher than its 52-week low of $166.82.
Target Corporation's Moving Average
Target Corporation's worth is under its 50-day moving average of $248.22 and above its 200-day moving average of $233.69.Previous days news about Target Corporation(TGT)
- According to Business Insider on Wednesday, 8 December, "The company announced a partnership with Target Corporation (NYSE:TGT) for inclusion in physical stores and on the Target.com website. "
- According to Business Insider on Thursday, 9 December, "Analyst Robert Ohmes compared grocery prices at conventional supermarkets Kroger Co (NYSE:KR) and Publix to prices at specialty grocers Sprouts Farmers Market Inc (NASDAQ:SFM) and Amazon.com, Inc.(NASDAQ:AMZN) subsidiary Whole Foods as well as mass retailers Walmart Inc (NYSE:WMT) and Target Corporation (NYSE:TGT)."